MBMegan E. Bunnell

Megan E. Bunnell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Megan E. Bunnell has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Case Report of Y-Chromosome Mosaicism in Turner Syndrome: Complementary Use of Multiple Genetic Platforms to Resolve a Complex Derivative Y-Chromosome

    by Aisha L. Siebert, Megan E. Bunnell, Selena Vanapruks, Scott Ryall, Frederick R. Bieber, Wen-Hann Tan, Melise Keays

  • The Prenatal Phenotype: Illustrating the Complexities of Genetic Testing and Interpretation With the Goal of Understanding the Fetal Presentation of Genetic Disease

    by Megan Bunnell, Briana O'LEary

    Advanced prenatal imaging and chromosomal microarray have improved detection of fetal anomalies, yet many structurally abnormal fetuses remain without a unifying diagnosis. This manuscript describes representative prenatal cases evaluated with genome sequencing (GS) or exome sequencing (ES), demonstrating how genomic data refine etiologic understanding, reshape counseling, and reveal the complexities of variant interpretation within the prenatal context. Three illustrative fetal cases were selected based on characteristic imaging findings, including short long bones, echogenic kidneys, multisystem anomalies, and severe limb reduction defects. All underwent detailed ultrasound, standard genetic evaluation, and ultimately GS or ES. Variants were classified using ACMG/AMP criteria with prenatal‐specific interpretive considerations. Diagnoses included a 17q12 deletion with concomitant ARID1B‐related Coffin–Siris syndrome, a de novo FRYL variant in the setting of multisystem anomalies, and a de novo KMT2E truncating variant identified alongside placental pathology supportive of treated leptospirosis. Findings alter recurrence risks, reveal dual diagnoses, and highlight prognostic complexities. Prenatal sequencing clarifies fetal diagnoses, informs reproductive planning, and refines risk counseling, yet interpretation is constrained by limited prenatal phenotyping and reliance on postnatal genotype–phenotype literature. Integration of GS/ES with imaging and multidisciplinary counseling is essential as sequencing becomes routine in perinatal care.

  • Universal Prenatal cfDNA‐Single Gene Disorder Screening for Autosomal Dominant Conditions in a Low‐Risk Cohort: A Cost‐Effectiveness Analysis

    by Megan E. Bunnell, Claire H. Packer, Sophie Adams, Yael Hoffman Sage

    Objective: The use of cell free fetal DNA has expanded to include autosomal dominant single gene conditions (cfDNA‐SGD). Our aim is to estimate the cost‐effectiveness of a cfDNA‐SGD panel in a general obstetric population as compared to offering this test only in the setting of anomalies. Methods: Using TreeAge software, we created a decision‐analytic model to compare outcomes of the universal cfDNA‐SGD. The screening conditions included in the current panel were separated into tiers (1, 2, 3) based on severity and life expectancy of the conditions. Outcomes included miscarriage after diagnostic procedure, termination, neonatal death, and the outcome of affected livebirth. The cost‐effectiveness threshold was set at $100,000 per QALY. Results: When applied to a theoretical cohort of 3.7 million individuals, the strategy of universal cfDNA‐SGD resulted in approximately 2979 fewer affected livebirths. Given the high costs of care associated with an affected liveborn, universal cfDNA‐SGD was projected to be cost‐saving in this model until the test cost exceeded $1094. The universal cfDNA‐SGD strategy was also projected to yield an additional 10,477 maternal QALYs. Conclusion: In this model, and under the assumptions specified, universal cfDNA‐SGD was projected to be cost‐saving and to yield additional maternal QALYs relative to ultrasound‐indicated cfDNA‐SGD. These are model‐based projections rather than observed outcomes; prospective implementation studies will be needed before any conclusion can be drawn about routine integration into prenatal care.

  • Open Access

    Left ventricular assist device in pregnancy: case report of a near-term delivery with multidisciplinary support

    by Megan E Bunnell, Tianjiao Ren, Tyler J Guidugli, Bushra W Taha, Katherine E Economy, Michael M Givertz

    Background: Left ventricular assist devices (LVADs) are utilized to treat end-stage heart failure (HF) refractory to pharmacologic and device-based therapies. LVAD use is considered a relative contraindication to pregnancy due to concerns for increased maternal and foetal risk. Nonetheless, there is an increasing prevalence of LVAD use in pregnant patients with advanced HF. Data have been limited to case reports without guidelines for pregnancy management, and there are no reports of delivery beyond the 34th week of pregnancy. Case: We present a case of a pregnant person with an LVAD who underwent an uncomplicated near-term induction with an unscheduled caesarean delivery without cardiac decompensation or hypertensive disorders. She received multidisciplinary care throughout her antenatal, intrapartum, and postpartum course. Conclusion: In LVAD patients with stable haemodynamics, managed by a multidisciplinary team in an appropriately resourced hospital, there may not be a need for planned preterm delivery.

  • Severe Early‐Onset Fetal Growth Restriction: The Yield of Antenatal and Postnatal Genetic Testing

    by Matthew H. Mossayebi, Sophie J. Adams, Megan E. Bunnell, Stephanie H. Guseh, Louise E. Wilkins‐Haug

    Objectives: We evaluated the diagnostic yield of karyotype (KT) and chromosomal microarray (CMA) with isolated severe FGR diagnosed before 32 weeks' gestation. Exome and genome sequencing (ES/GS) level data were available in a subset of this population. Method: We performed a retrospective review of singleton pregnancies (delivered 2022–2025) with estimated fetal weight or abdominal circumference < 3rd percentile before 32 weeks' gestation, no sonographic structural anomalies, and diagnostic testing (KT, CMA, ES, or GS) via amniocentesis or cord blood. Cases with abnormal cell‐free DNA were excluded. Results: Forty cases were included (mean diagnosis 26.8 weeks). Testing was performed via amniocentesis in 42% and cord blood in 58%. All KT (27/40) were normal. CMA (39/40) identified one pathogenic CNV (2.5%) and three (7.5%) variants of uncertain significance (VUS). Four (10%) showed ≥ 1 region of absence of heterozygosity (AOH) > 10Mb; one revealed maternal uniparental disomy of chromosome 6. Sequencing ( N = 10) detected one VUS in COL1A1 . Acute viral infection was not observed in any of the cases. Conclusions: CMA was diagnostic in 2/39 (5.1%) cases, a pathogenic CNV implicating the SHOX gene, and maternal UPD 6, which were consistent with FGR. There was a remarkable rate (10%) of AOH. Further investigation, including placental studies and genome sequencing, may elucidate whether AOH is a contributing factor for FGR.

  • Risk factors for delayed termination of pregnancy following increased nuchal translucency

    by Megan E. Bunnell, Sophie Adams, Andrea Pelletier, Yael Hoffman Sage

    Objectives: Termination of pregnancy after increased nuchal translucency (NT) is a common occurrence. This study aimed to identify characteristics of a cohort with a NT >= 3.0 mm who underwent a pregnancy termination >= 15 weeks compared with those who terminated = 3.0 mm identified within our department over an 11-year period (2010-2021) (n = 689) were retrospectively examined and characteristics of the cohort of increased NTs ending in termination were further categorized.Results: There were 221 (32.1%) individuals with an increased NT (>= 3 mm) who underwent a termination of pregnancy within our study period (2010-2021). Pregnancy termination occurred at a gestational age = 15 weeks in 59 individuals. Pregnant individuals without positive NIPT for aneuploidy were at a higher risk for a >= 15-week termination (p = 0.004). In 29% (17/59) of late terminations, there were additional imaging findings after the NT scan (ultrasound, echocardiogram, magnetic resonance imaging) that ultimately triggered the decision to pursue termination.Conclusions: As the options for workup of an increased NT expand, potential delays in decision-making surrounding termination increase. This study identifies multiple reasons for delayed termination and proposes several approaches to care aimed at maximizing diagnostic information by imaging and diagnostic testing in an expedited manner.

  • Open Access

    Case Series of Reproductive Outcomes after Surgical Correction of Obstructed Hemivagina in OHVIRA

    by Megan E. Bunnell, Danielle T. Cipres, Marc R. Laufer

    Obstructed hemivagina and ipsilateral renal anomaly (OHVIRA) is a rare congenital developmental syndrome manifested by uterine duplication, lower genital tract obstruction, and unilateral renal anomaly. Literature on reproductive outcomes in this patient population is limited. The aim of this study is to describe obstetric outcomes after surgical correction of obstructed hemivagina in a longitudinal cohort of patients with a diagnosis of OHVIRA. All cases of OHVIRA presenting to a single tertiary care children's hospital from 1990 to 2021 were retrospectively reviewed. Three cases demonstrating a variety of clinically important reproductive outcomes are described in detail including risks such as retained products, endometritis, preterm labor, and malpresentation. Understanding the reproductive outcomes associated with this diagnosis is important for practitioners seeking to counsel and care for patients with this diagnosis. This case series demonstrates a wide array of potential gynecologic and obstetric risks, though ultimately with successful term and near-term pregnancies.


  • Increased use of diagnostic testing after increased nuchal translucency: The influence of non‐invasive prenatal testing and chromosomal microarray

    by Megan E. Bunnell, Sophie Adams, Andrea Pelletier, Yael Hoffman Sage

    Objective: The utilization of non‐invasive prenatal testing (NIPT) and chromosomal microarray (CMA) has significantly altered the options for testing following the diagnosis of an increased nuchal translucency (NT). This study defines the rates of utilization of diagnostic testing in the pre‐NIPT, pre‐CMA, and post‐CMA eras.Methods: We retrospectively examined NT scans performed in our department from January 2010 to December 2020 and identified all NTs ≥3.0 mm for analysis. We divided our data into three distinct periods (2010–2012, 2013–2016, and 2017–2020) corresponding to our institutional practice shifts in recommending and offering use of NIPT (2013) and CMA (2016), respectively.Results: 689 patients with NT ≥ 3.0 mm met inclusion criteria in our study, of which 355 (51.5%) individuals underwent diagnostic testing and 334 (48.5%) did not. There was a significant decline in rates of diagnostic testing with NIPT (2013), which has returned to pre‐NIPT levels with the availability of microarray.Conclusions: Since the routine use of CMA (2016), the rates of diagnostic testing for increased NT have returned to pre‐NIPT levels. This study validates data suggesting an initial decline in the rates of diagnostic testing following abnormal NT but suggests that the decline may be reversing in the post‐CMA era due to a rise in rates of chorionic villus sampling.


  • Use of preimplantation genetic testing for monogenic disorders and subsequent prenatal care and diagnostic testing

    by Megan E. Bunnell, Lori J. Dobson, Andrea Lanes, Elizabeth S. Ginsburg

    Objective: The goal of preimplantation genetic testing for monogenic or single gene defects (PGT‐M) is to identify inherited pathogenic variants in the embryo prior to embryo transfer, increasing the likelihood of an unaffected child. Prenatal diagnostic testing is recommended to confirm the results of PGT‐M. The purpose of this study was to characterize the population undergoing PGT‐M over time.Methods: This retrospective study examined patients who had a positive pregnancy test after PGT‐M from 2012 to 2019. A query of the internal assisted reproductive technology database and chart review were used.Results: One hundred and 42 patients completed IVF cycles for PGT‐M during this time period and progressed past 10 weeks gestation. There were more PGT‐M cycles over time with 46 cycles between 2012 and 2015 and 96 cycles between 2016 and 2019. Patients varied on the decision to pursue prenatal diagnostic testing after PGT‐M. For those with known follow‐up (130/142), 16 patients underwent diagnostic testing (12%) and 114 did not.Conclusion: As PGT‐M is increasingly utilized prior to pregnancy, it is important for genetic counselors and OB/GYNs to understand the characteristics and outcomes of the population of patients undergoing PGT‐M, including how to counsel about the residual risk of an affected pregnancy after PGT‐M.